https://pimreceptor.com/index.....php/evaluation-of-ti
The event (new-onset and recurrence) of uveitis ended up being evaluated retrospectively in like clients getting different TNF inhibitor therapies (adalimumab [ADA], infliximab [IFX], etanercept [ETN], and golimumab [GOL]) for the management of spondyloarthritis from 2005 to 2018. Kaplan-Meier analysis ended up being performed to determine the cumulative occurrence rates of uveitis during TNF inhibitor therapy, and a log-rank test was used to analyse differences between the survival c
Like
Comment
Share
